To the content

Imprint

Media owner and publisher:

AOP Orphan Pharmaceuticals GmbH
Member of the AOP Health Group

Leopold-Ungar-Platz 2
1190 Vienna, Austria 
Tel.: + 43 1 503 72 44
Fax.: +43 1 503 72 44 5
E-Mail: office[at]aoporphan.com

Managing Directors

Dr. Martin Steinhart and Bernhard Nachbaur, LL.M.

Company Purpose: 

Manufacturing and wholesale of medicines and poisons. Manufacturing, processing and wholesale of medical devices, insofar as these activities are not subject to any other regulation.

VAT Number: ATU57344706
Company registration number: FN 237770m
Company Register Court: Commercial court: Vienna, Austria
Headquarters: Vienna, Austria

Applicable Rules and Regulations

Austrian Drug Law (AMG)
Austrian Medical Product Law (MPG
Austrian Trade, Commerce and Industry Regulation Act (Gewerbeordnung GewO 1994)

Regulatory Authority/Commercial Authority:          

  • Municipal authority for the 18th/19th District in Vienna, Austria conducting general business supervision
  • Austrian Federal Ministry of Health conducting supervisory control
  • AGES, Austrian Agency for Health and Food Safety
  • Member of Economic Chamber Vienna, Austria

Online Dispute Resolution:

Consumers have the possibility to submit complaints to the EU online dispute resolution platform:
You can also send any complaints to the above e-mail address.

Website              

www.aop-health.com
Concept, UX & UI Design, and Technical Development:
FONDA – Agentur für digitale Medien und Kommunikation

Website Purpose             

Providing information about rare diseases to the general public

Drug Safety

Reporting of Adverse Drug Reactions: drugsafety[at]aoporphan.com

Disclaimer:

Health Information: this website may contain information referring to medical and health topics. This relevant information however does not offer an alternative to the advice of physicians, pharmacists or other representatives of the medical sector and are not to be used for self-diagnosis or for the diagnosis of others. Scientific data as well as information concerning the development of products or therapies are subject to premier publishing and thus, are always open to any type of change.

To the main navigation